Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,908
archived clinical trials in
Renal Impairment / Chronic Kidney Disease

Identification of Gene and Protein Markers of Kidney Injury in Aminoglycoside-treated Children
Assessment of Gene and Urinary Protein Expression in Aminoglycoside-treated and Untreated Infants, Children and Adolescents
Status: Enrolling
Updated:  1/30/2016
University of Lousiville
mi
from
Louisville, KY
Identification of Gene and Protein Markers of Kidney Injury in Aminoglycoside-treated Children
Assessment of Gene and Urinary Protein Expression in Aminoglycoside-treated and Untreated Infants, Children and Adolescents
Status: Enrolling
Updated: 1/30/2016
University of Lousiville
mi
from
Louisville, KY
Click here to add this to my saved trials
Identification of Gene and Protein Markers of Kidney Injury in Aminoglycoside-treated Children
Assessment of Gene and Urinary Protein Expression in Aminoglycoside-treated and Untreated Infants, Children and Adolescents
Status: Enrolling
Updated:  1/30/2016
Virginia Commonwealth University
mi
from
Richmond, VA
Identification of Gene and Protein Markers of Kidney Injury in Aminoglycoside-treated Children
Assessment of Gene and Urinary Protein Expression in Aminoglycoside-treated and Untreated Infants, Children and Adolescents
Status: Enrolling
Updated: 1/30/2016
Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
Validation of Transesophageal Echocardiography (TEE) to Measure Renal Resistive Index and to Predict Renal Injury
Validation of Transesophageal Echocardiography With to Measure Renal Resistive Index and to Predict Acute Kidney Injury
Status: Enrolling
Updated:  2/1/2016
University Hospital
mi
from
Newark, NJ
Validation of Transesophageal Echocardiography (TEE) to Measure Renal Resistive Index and to Predict Renal Injury
Validation of Transesophageal Echocardiography With to Measure Renal Resistive Index and to Predict Acute Kidney Injury
Status: Enrolling
Updated: 2/1/2016
University Hospital
mi
from
Newark, NJ
Click here to add this to my saved trials
An Exploratory Study to Evaluate FMX-8 to Treat Anemia in CKD
An Exploratory, Uncontrolled, Open-labeled Trial to Evaluate the Effect of FMX-8 Treatment for Anemia in Patients With Chronic Kidney Disease (CKD), Stage 4 or 5
Status: Enrolling
Updated:  2/1/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
An Exploratory Study to Evaluate FMX-8 to Treat Anemia in CKD
An Exploratory, Uncontrolled, Open-labeled Trial to Evaluate the Effect of FMX-8 Treatment for Anemia in Patients With Chronic Kidney Disease (CKD), Stage 4 or 5
Status: Enrolling
Updated: 2/1/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease
Status: Enrolling
Updated:  2/2/2016
UCLA
mi
from
Los Angeles, CA
FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease
Status: Enrolling
Updated: 2/2/2016
UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal Function
A Phase 1 Study of the Pharmacokinetics, Safety, and Tolerability of ALKS5461 in Subjects With Renal Impairment
Status: Enrolling
Updated:  2/3/2016
Alkermes Investigational Site
mi
from
Denver, CO
Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal Function
A Phase 1 Study of the Pharmacokinetics, Safety, and Tolerability of ALKS5461 in Subjects With Renal Impairment
Status: Enrolling
Updated: 2/3/2016
Alkermes Investigational Site
mi
from
Denver, CO
Click here to add this to my saved trials
Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal Function
A Phase 1 Study of the Pharmacokinetics, Safety, and Tolerability of ALKS5461 in Subjects With Renal Impairment
Status: Enrolling
Updated:  2/3/2016
Alkermes Investigational Site
mi
from
Orlando, FL
Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal Function
A Phase 1 Study of the Pharmacokinetics, Safety, and Tolerability of ALKS5461 in Subjects With Renal Impairment
Status: Enrolling
Updated: 2/3/2016
Alkermes Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials
Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal Function
A Phase 1 Study of the Pharmacokinetics, Safety, and Tolerability of ALKS5461 in Subjects With Renal Impairment
Status: Enrolling
Updated:  2/3/2016
Alkermes' Investigational Study Site
mi
from
Minneapolis, MN
Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal Function
A Phase 1 Study of the Pharmacokinetics, Safety, and Tolerability of ALKS5461 in Subjects With Renal Impairment
Status: Enrolling
Updated: 2/3/2016
Alkermes' Investigational Study Site
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Ferric Citrate in Patients With End-Stage Renal Disease on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Enrolling
Updated:  2/3/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Ferric Citrate in Patients With End-Stage Renal Disease on Dialysis
A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Status: Enrolling
Updated: 2/3/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy
A Randomized Controlled Trial of Mycophenolate Mofetil in Patients With IgA Nephropathy
Status: Enrolling
Updated:  2/4/2016
St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy
A Randomized Controlled Trial of Mycophenolate Mofetil in Patients With IgA Nephropathy
Status: Enrolling
Updated: 2/4/2016
St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
An Ascending Dose Study to Assess Safety, Tolerability, PK/PD of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction
A Partially-blinded, Randomized, Placebo-controlled, Adaptive Single and Multiple Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction
Status: Enrolling
Updated:  2/4/2016
Novartis Investigative Site
mi
from
Orlando, FL
An Ascending Dose Study to Assess Safety, Tolerability, PK/PD of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction
A Partially-blinded, Randomized, Placebo-controlled, Adaptive Single and Multiple Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction
Status: Enrolling
Updated: 2/4/2016
Novartis Investigative Site
mi
from
Orlando, FL
Click here to add this to my saved trials
An Ascending Dose Study to Assess Safety, Tolerability, PK/PD of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction
A Partially-blinded, Randomized, Placebo-controlled, Adaptive Single and Multiple Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction
Status: Enrolling
Updated:  2/4/2016
Novartis Investigative Site
mi
from
Knoxville, TN
An Ascending Dose Study to Assess Safety, Tolerability, PK/PD of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction
A Partially-blinded, Randomized, Placebo-controlled, Adaptive Single and Multiple Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction
Status: Enrolling
Updated: 2/4/2016
Novartis Investigative Site
mi
from
Knoxville, TN
Click here to add this to my saved trials
Double-Blind Placebo-Controlled CIN Trial
Phase IV Randomized Double-Blinded Placebo-Controlled Noninferiority Study of the Effect of Intravenous Low-Osmolality Iodinated Contrast Material On Renal Function in Postoperative Adults With Stage IIIb or Stage IV Chronic Kidney Disease
Status: Enrolling
Updated:  2/5/2016
University of Michigan Hospital Department of Radiology
mi
from
Ann Arbor, MI
Double-Blind Placebo-Controlled CIN Trial
Phase IV Randomized Double-Blinded Placebo-Controlled Noninferiority Study of the Effect of Intravenous Low-Osmolality Iodinated Contrast Material On Renal Function in Postoperative Adults With Stage IIIb or Stage IV Chronic Kidney Disease
Status: Enrolling
Updated: 2/5/2016
University of Michigan Hospital Department of Radiology
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated:  2/10/2016
Southwest Kidney Institute, PLC
mi
from
Tempe, AZ
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated: 2/10/2016
Southwest Kidney Institute, PLC
mi
from
Tempe, AZ
Click here to add this to my saved trials
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated:  2/10/2016
Southwest Clinical Research Institute
mi
from
Tempe, AZ
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated: 2/10/2016
Southwest Clinical Research Institute
mi
from
Tempe, AZ
Click here to add this to my saved trials
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated:  2/10/2016
Capital Nephrology Clinical Research
mi
from
Sacramento, CA
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated: 2/10/2016
Capital Nephrology Clinical Research
mi
from
Sacramento, CA
Click here to add this to my saved trials
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated:  2/10/2016
Boise Kidney & Hypertension Institute, PLLC
mi
from
Caldwell, ID
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated: 2/10/2016
Boise Kidney & Hypertension Institute, PLLC
mi
from
Caldwell, ID
Click here to add this to my saved trials
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated:  2/10/2016
Renal Associates of Baton Rouge
mi
from
Baton Rouge, LA
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated: 2/10/2016
Renal Associates of Baton Rouge
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated:  2/10/2016
Tufts Medical Center
mi
from
Boston, MA
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated: 2/10/2016
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated:  2/10/2016
Washington University
mi
from
St. Louis, MO
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated: 2/10/2016
Washington University
mi
from
St. Louis, MO
Click here to add this to my saved trials
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated:  2/10/2016
New York University - HHC CTSI Clinical Research Center
mi
from
New York, NY
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated: 2/10/2016
New York University - HHC CTSI Clinical Research Center
mi
from
New York, NY
Click here to add this to my saved trials
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated:  2/10/2016
Nephrology/Hypertension Specialists
mi
from
Doylestown, PA
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated: 2/10/2016
Nephrology/Hypertension Specialists
mi
from
Doylestown, PA
Click here to add this to my saved trials
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated:  2/10/2016
Doylestown Hospital
mi
from
Doylestown, PA
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated: 2/10/2016
Doylestown Hospital
mi
from
Doylestown, PA
Click here to add this to my saved trials
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated:  2/10/2016
San Antonio Kidney Disease Center Physicians Group
mi
from
San Antonio, TX
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated: 2/10/2016
San Antonio Kidney Disease Center Physicians Group
mi
from
San Antonio, TX
Click here to add this to my saved trials
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated:  2/10/2016
Renal Associates, PA
mi
from
San Antonio, TX
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated: 2/10/2016
Renal Associates, PA
mi
from
San Antonio, TX
Click here to add this to my saved trials
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated:  2/10/2016
University of Virginia Health System - Nephrology
mi
from
Charlottesville, VA
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated: 2/10/2016
University of Virginia Health System - Nephrology
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated:  2/10/2016
University of Virginia Health System
mi
from
Charlottesville, VA
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated: 2/10/2016
University of Virginia Health System
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated:  2/10/2016
The Polyclinic
mi
from
Seattle, WA
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated: 2/10/2016
The Polyclinic
mi
from
Seattle, WA
Click here to add this to my saved trials
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated:  2/10/2016
Renal Remission and Hypertension Clinic
mi
from
Silverdale, WA
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated: 2/10/2016
Renal Remission and Hypertension Clinic
mi
from
Silverdale, WA
Click here to add this to my saved trials
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated:  2/10/2016
Southwest Kidney Institute, PLC
mi
from
Phoenix, AZ
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated: 2/10/2016
Southwest Kidney Institute, PLC
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated:  2/10/2016
Boise Kidney and Hypertension Institute
mi
from
Meridian, ID
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated: 2/10/2016
Boise Kidney and Hypertension Institute
mi
from
Meridian, ID
Click here to add this to my saved trials
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated:  2/10/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated: 2/10/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated:  2/10/2016
Doylestown Hospital MRI
mi
from
Doylestown, PA
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated: 2/10/2016
Doylestown Hospital MRI
mi
from
Doylestown, PA
Click here to add this to my saved trials
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated:  2/10/2016
Monash Medical Centre
mi
from
Clayton,
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Enrolling
Updated: 2/10/2016
Monash Medical Centre
mi
from
Clayton,
Click here to add this to my saved trials
A Study To Investigate The Pharmacokinetics, Safety And Tolerability Of An Intravenous And Oral Form Of A Compound In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function
An Open-label, 2-way Crossover Study To Investigate The Pharmacokinetics, Safety And Tolerability Of Iv Cp-70429 And Oral Pf-03709270 In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function
Status: Enrolling
Updated:  2/10/2016
Centurion Clinical Research
mi
from
Indianapolis, IN
A Study To Investigate The Pharmacokinetics, Safety And Tolerability Of An Intravenous And Oral Form Of A Compound In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function
An Open-label, 2-way Crossover Study To Investigate The Pharmacokinetics, Safety And Tolerability Of Iv Cp-70429 And Oral Pf-03709270 In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function
Status: Enrolling
Updated: 2/10/2016
Centurion Clinical Research
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study To Investigate The Pharmacokinetics, Safety And Tolerability Of An Intravenous And Oral Form Of A Compound In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function
An Open-label, 2-way Crossover Study To Investigate The Pharmacokinetics, Safety And Tolerability Of Iv Cp-70429 And Oral Pf-03709270 In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function
Status: Enrolling
Updated:  2/10/2016
Pfizer Clinical Research Unit
mi
from
Bruxelles,
A Study To Investigate The Pharmacokinetics, Safety And Tolerability Of An Intravenous And Oral Form Of A Compound In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function
An Open-label, 2-way Crossover Study To Investigate The Pharmacokinetics, Safety And Tolerability Of Iv Cp-70429 And Oral Pf-03709270 In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function
Status: Enrolling
Updated: 2/10/2016
Pfizer Clinical Research Unit
mi
from
Bruxelles,
Click here to add this to my saved trials
Sirolimus Conversions in African-American Renal Transplant Recipients
A Pilot Study Comparing Two Different Sirolimus-based Transition Regimens in African-American Renal Transplant Recipients
Status: Enrolling
Updated:  2/12/2016
Medical University of South Carolina
mi
from
Charleston, SC
Sirolimus Conversions in African-American Renal Transplant Recipients
A Pilot Study Comparing Two Different Sirolimus-based Transition Regimens in African-American Renal Transplant Recipients
Status: Enrolling
Updated: 2/12/2016
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients: A Randomized Clinical Trial
Status: Enrolling
Updated:  2/15/2016
DCI - Redding
mi
from
Redding, CA
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients: A Randomized Clinical Trial
Status: Enrolling
Updated: 2/15/2016
DCI - Redding
mi
from
Redding, CA
Click here to add this to my saved trials
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients: A Randomized Clinical Trial
Status: Enrolling
Updated:  2/15/2016
DCI - Albany
mi
from
Albany, GA
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients: A Randomized Clinical Trial
Status: Enrolling
Updated: 2/15/2016
DCI - Albany
mi
from
Albany, GA
Click here to add this to my saved trials
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients: A Randomized Clinical Trial
Status: Enrolling
Updated:  2/15/2016
DCI - Shreveport
mi
from
Shreveport, LA
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients: A Randomized Clinical Trial
Status: Enrolling
Updated: 2/15/2016
DCI - Shreveport
mi
from
Shreveport, LA
Click here to add this to my saved trials
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients: A Randomized Clinical Trial
Status: Enrolling
Updated:  2/15/2016
DCI - Boston
mi
from
Boston, MA
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients: A Randomized Clinical Trial
Status: Enrolling
Updated: 2/15/2016
DCI - Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients: A Randomized Clinical Trial
Status: Enrolling
Updated:  2/15/2016
DCI- Columbia
mi
from
Columbia, MO
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients: A Randomized Clinical Trial
Status: Enrolling
Updated: 2/15/2016
DCI- Columbia
mi
from
Columbia, MO
Click here to add this to my saved trials
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients: A Randomized Clinical Trial
Status: Enrolling
Updated:  2/15/2016
DCI - Kansas City
mi
from
Kansas City, MO
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients: A Randomized Clinical Trial
Status: Enrolling
Updated: 2/15/2016
DCI - Kansas City
mi
from
Kansas City, MO
Click here to add this to my saved trials
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients: A Randomized Clinical Trial
Status: Enrolling
Updated:  2/15/2016
DCI- Omaha
mi
from
Omaha, NE
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients: A Randomized Clinical Trial
Status: Enrolling
Updated: 2/15/2016
DCI- Omaha
mi
from
Omaha, NE
Click here to add this to my saved trials
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients: A Randomized Clinical Trial
Status: Enrolling
Updated:  2/15/2016
DCI - New Brunswick
mi
from
New Brunswick, NJ
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients: A Randomized Clinical Trial
Status: Enrolling
Updated: 2/15/2016
DCI - New Brunswick
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients: A Randomized Clinical Trial
Status: Enrolling
Updated:  2/15/2016
DCI - North Brunswick
mi
from
North Brunswick, NJ
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients: A Randomized Clinical Trial
Status: Enrolling
Updated: 2/15/2016
DCI - North Brunswick
mi
from
North Brunswick, NJ
Click here to add this to my saved trials
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients: A Randomized Clinical Trial
Status: Enrolling
Updated:  2/15/2016
DCI - Philadelphia
mi
from
Philadelphia, PA
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients: A Randomized Clinical Trial
Status: Enrolling
Updated: 2/15/2016
DCI - Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients: A Randomized Clinical Trial
Status: Enrolling
Updated:  2/15/2016
DCI - Knoxville
mi
from
Knoxville, TN
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients: A Randomized Clinical Trial
Status: Enrolling
Updated: 2/15/2016
DCI - Knoxville
mi
from
Knoxville, TN
Click here to add this to my saved trials
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients: A Randomized Clinical Trial
Status: Enrolling
Updated:  2/15/2016
DCI - Maryville
mi
from
Maryville, TN
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients: A Randomized Clinical Trial
Status: Enrolling
Updated: 2/15/2016
DCI - Maryville
mi
from
Maryville, TN
Click here to add this to my saved trials
Early Identification and Action in CKD
Early Identification and Action in CKD
Status: Enrolling
Updated:  2/15/2016
Geisinger Health System
mi
from
Danville, PA
Early Identification and Action in CKD
Early Identification and Action in CKD
Status: Enrolling
Updated: 2/15/2016
Geisinger Health System
mi
from
Danville, PA
Click here to add this to my saved trials